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The World Health Organization deﬁnes adherence as the
extent to which a person’s behaviour - taking medication,
following a diet, and/or executing lifestyle changes -
corresponds with agreed recommendations from a health-
care provider.1 Although often used interchangeably with
the term ‘compliance’, adherence is preferred by many as it
acknowledges the patient’s role in the decision-making
process.2 It has been claimed that increasing the effectiveness
of adherence interventions may have a far greater impact on
the health of the population than any improvement in speciﬁc
medical treatments.3
Non-adherence to treatment is a major barrier to
effective treatment in psychiatry, particularly in individuals
with psychotic disorders. Rates of non-adherence vary
between 24 and 40% based on medication reﬁll rates
available from pharmacy records.4,5 This is understandable
in view of the different populations, variety of diagnoses,
variable follow-up periods and, most importantly, the
different deﬁnitions and measurement methods used in
research.6 It has been reported in the literature that non-
adherence rates to medication for bipolar disorder typically
range between 20 and 60%, with an average of 40%.7-9 In
schizophrenia, a systematic review of 39 studies reported a
mean rate of medication non-adherence at 41%.10 When
the analysis was restricted to the ﬁve methodologically most
rigorous studies, which included deﬁning adherence as taking
medication at least 75% of the time, the non-adherence rate
increased to 50%.10 Non-adherence to treatment in
schizophrenia is often associated with potentially severe
clinical consequences.11,12 It is also estimated that up to 40%
of the total annual cost of schizophrenia, which amounts to
£400 million in the UK, could be due to non-adherence to
treatment.13
The National Institute for Health and Care Excellence
(NICE) guidelines14,15 recommend that treatment adherence
be regularly monitored in patients with schizophrenia but
there is relatively little information about how this is done in
clinical practice. In general, doctors uniformly underestimate
the degree of non-adherence in their patients.16
Aims
This audit was aimed at investigating whether medication
adherence is monitored during the follow-up of patients
diagnosed with schizophrenia or schizoaffective disorder.
We also evaluated the ways in which medication adherence
is discussed during out-patient reviews and recommend
practice improvement.
Method
We conducted a retrospective audit in 50 patients
presenting to the out-patient follow-up clinic in two UK
community mental health teams providing treatment for
patients within the complex care team. The clinics were
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Aims and method To investigate whether medication adherence is monitored
during follow-up in out-patient reviews. A retrospective audit was carried out with a
sample of 50 follow-up patients with a diagnosis of schizophrenia or schizoaffective
disorder. Following this, interventions were made prior to the re-audit (including text
messaging clinicians and prompt sheets in the out-patient department to encourage
adherence discussions).
Results There was an improvement on all the standards set for this audit following
the interventions. More doctors had discussed medication adherence (62% second
cycle v. 50% ﬁrst cycle) with their patient and there was increased discussion and
documentation regarding medication side-effects (60% second cycle v. 30% ﬁrst
cycle). More clinicians discussed the response to medication (60% second cycle v.
46% ﬁrst cycle).
Clinical implications Treatment adherence is not regularly monitored or recorded in
clinical notes in routine psychiatric out-patient appointments. This highlights the need
for regular training to improve practice.
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based in the Black Country Partnership NHS Foundation
Trust. Only patients with a diagnosis of schizophrenia or
schizoaffective disorder who were currently under out-
patient follow-up were included. A random sample of
patients was generated by taking every ﬁfth patient from
the list provided by the clinic administrator. The last clinic
letter was reviewed to collect data via the medical notes and
electronic healthcare records.
The standards were identiﬁed using the NICE guide-
lines on medicines adherence and treatment of psychosis
and schizophrenia.14,15 The guidelines have emphasised
what should be reviewed and discussed in out-patient
clinics. Speciﬁcally, they recognise that the treatment
should be regularly and systematically reviewed to monitor
treatment adherence. During the titration of treatment the
following should be regularly monitored:
. response to treatment, including changes in symptoms
and behaviour
. side-effects of treatment
. emergence of movement disorders
. weight
. waist circumference
. pulse and blood pressure
. adherence
. overall physical health.
The NICE guideline on treatment adherence explicitly
states that when reviewing medication the clinician should
enquire about adherence:
‘If non adherence is identiﬁed, clarify possible causes and agree
any action with the patient. Any plan should include a date for
a follow up review.’15
As a consequence, the standards set out for this auditwere that:
(a) 100% of patients should have a discussion with the
doctor regarding the medication, including response
and side-effects
(b) 100% of patients should have a discussion with the
doctor regarding adherence to medication
(c) if medication is stopped, reasons for this should be
explored.
In light of this we constructed a data collection tool for the
audit (Box 1).
Results
Audit cycle 1
Data were collected over a period of 4 weeks. The results
showed that adherence was discussed and documented only
in 50% of consultations, side-effects were discussed only in
30% of consultations and response to medication was
discussed in 46% of cases. Further questioning in terms of
assessing adherence appeared to be poorly done, with less
than 10% of consultations assessing adherence in greater
detail.
The results of this initial audit highlighted either a gap
in clinical practice or poor documentation. The results were
discussed with colleagues in the weekly audit meeting in the
hospital and recommendations were made to improve the
practice (Box 2)
As a consequence of the initial audit, a change in
practice was brought about by introducing information
sheets in each clinic room with possible questions
concerning adherence to ask when assessing patients in
clinic. A brief session on adherence was also added to the
junior doctor induction. Then, a text message reminder was
sent to colleagues. This included consultants, specialty
doctors and trainees (core and foundation year 2) at the
start of each clinic for a period of 3 months. The text
message was very brief, reminding colleagues to discuss
adherence with their patients in clinic. The colleagues’
consent was sought prior to this 3-month trial. We initially
planned to send the text reminders using NHS.net, which
provided such a service, but that stopped in early 2015. As a
result, we sent out a group message using the work mobile
phone.
Following this period a re-audit was carried out. It
again focused on patients with schizophrenia and schizoaf-
fective disorder but only spanned the intervention period of
the prior 3 months.
Re-audit
As before, a random sample of 50 patients was selected. A
similar procedure was carried out, but only patients
reviewed after the initial audit were included. The same
data collection tool was used (Box 1). The results are
illustrated in Fig. 1.
The results indicated an improvement in all three key
comparisons. More doctors had discussed medication
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Box 1 Information gathering tool for the audit
. Was adherence to medication discussed?
. Did the clinician ask the patient about any periods when they
had missed taking medication?
. Did the patient mention missing any medication and was this
discussed with the patient?
. Had the patient missed any medication over the past month?
. Were side-effects of the medication discussed?
. Did the clinician ask the patient whether these side-effects
had impact on their adherence?
. If non-adherence was noted to be a signiﬁcant problem, were
any strategies to improve adherence discussed?
. Was the response to medication discussed?
. If medication was stopped, were reasons for this explored?
Box 2 Recommendations following the ﬁrst audit cycle
1 Provide formal training to doctors regarding assessing
adherence during the induction for junior trainees and
through a session delivered in the local teaching programme
for the rest of the clinicians.
2 Provide a list of questions to be asked regarding adherence in
clinics.
3 Provide a text reminder to doctors on clinic days to remind
them to assess adherence.
4 Re-audit following implementation of changes.
adherence with their patient over the past 3 months (62% v.
50%, P = 0.22), and there was increased discussion with
patients and documentation of side-effects (60% v. 30%,
P = 0.0025). More clinicians discussed the response to
medication with their patients in the second audit (60%
(n = 30) v. 46% (n = 23), P = 0.16). The results regarding
further questions about adherence continued to be poor,
with only 4% (n = 2) asking about whether the patient had
missed any doses of medication. However, it was felt this
may be secondary to a lack of documentation rather than
being a true reﬂection of practice.
P-values revealed a signiﬁcant difference in the two
audits for the discussion about side-effects, with an
improvement noted following the interventions. However,
there was no signiﬁcant difference on discussions about
adherence and response to medication between the two
audits.
Discussion
Improving treatment adherence is at the heart of clinical
psychiatry. It requires building a therapeutic relationship
with patients, understanding their needs and tailoring
treatment accordingly. Monitoring treatment adherence is
a continuous process during which the need to continue
medication in the long term is regularly stressed. We need
to identify the barriers and help patients and carers to
overcome these. This can only be achieved if the treatment
is regularly monitored for its efﬁcacy, side-effect burden and
acceptability to patients.
This audit presents a rather disappointing picture of
the conversation about treatment adherence, which is not
common in clinical encounters. Such discussions took place
in just half of the consultations, whereas questions about
possible side-effects and response to medication were raised
even less frequently. The ﬁrst variable improved to about
60% after regular reminders and inclusion of this topic in
the junior doctor induction, but this result was not
statistically signiﬁcant. However, the results were statisti-
cally signiﬁcant concerning discussions about side-effects,
with a signiﬁcant improvement noted following the
interventions. This perhaps highlights the need for regular
training to improve the monitoring of treatment adherence.
It has been shown that simple questions about different
aspects of medication-taking behaviours can be effective in
improving treatment adherence.17 Most of the information
regarding assessment of adherence is based on clinical
experience or limited research. Clinicians can start by
asking patients ‘Have you missed any pills in the past week?’
A positive response indicates there may be a problem with
adherence. Clinicians should bear in mind that patients
tend to overestimate their actual adherence to therapy and
that the accuracy of the self-report depends on the patient’s
cognitive abilities, attitudes and openness towards the
therapist.6 Some simple questions that can be asked in
routine clinical care include: ‘How are you taking your
medications?’, ‘Have you ever forgotten to take your
medications?’, ‘Are you experiencing any adverse drug
reactions?’, ‘How are you feeling since you started the
medication?’6
The results of the audit should be interpreted in the
light of some limitations. It is possible that these questions
are asked but not regularly documented. Patient medication
adherence was not directly measured in the audit. The study
had a small sample size that represents a snapshot of
clinical encounters, which may not be generalisable. The
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Fig. 1 Comparison of key audit results.
43
discussion about treatment adherence may have taken place
in different settings such as the in-patient setting or with
other members of the multidisciplinary team such as the
community psychiatric nurse. We used text message
reminders, which has helped the clinicians ask about
adherence. Text messages have often been used to remind
patients abut medication, but they have not been commonly
used to alter the clinicians’ behaviour, and can prove a
simple and effective method for improving adherence with
good practice.
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